Establishment Labs Holdings Inc. (ESTA) SEC Filings & Earnings Calls
EquiReason read 14 Establishment Labs Holdings Inc. SEC filings in the last 12 months. Latest: 8-K on 2026-10-15 — Establishment Labs entered Amendment No. 3 to its Master Supply Agreement with NuSil Technology LLC, extending the initial term to December 31, 2031, with automatic renewals. The a.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 1.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
15 Oct 20268-K · 1.01Establishment Labs entered Amendment No. 3 to its Master Supply Agreement with NuSil Technology LLC, extending the initial term to December 31, 2031, with automatic renewals. The amendment covers medical-grade silicone supply, payment termsopen
Risks flagged
No financial terms disclosed; reliance on single supplier for critical material remains a concentration risk.
“The agreement covers NuSil's manufacture and sale of medical-grade silicone for use in specified ELSA products.”
7 Aug 202610-QEstablishment Labs reported strong Q2 2026 revenue growth of 31.7% YoY and gross margin expansion to 70.6%, driven by U.S. market after FDA approval.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $68M | +32% y/y |
| Net loss · Q2-2026 | $-12M | |
| Gross margin · Q2-2026 | 70.6% | |
| Cash · 2026-06-30 | $71M |
Risks flagged
Accumulated deficit and ongoing losses
“As of June 30, 2026, we had an accumulated deficit of $520.9 million. Since our inception, we have generated losses and expect to continue to generate losses in the near term.” · word for word
High debt and interest expense
“Interest expense increased to $7.0 million for Q2 2026 from $6.0 million in Q2 2025 due to increase in debt associated with the Amended Credit Agreement.”
6 Aug 20268-K · 2.02Revenue $67.5M (+31.7% YoY), gross margin 70.6% (up from 68.8%), adjusted EBITDA positive $3.7M vs -$8.5M, guidance raised to $269-271M from $266.5-268.5M, cash improved.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q2-2026 | $68M | +32% y/y |
| Gross margin · Q2-2026 | 70.6% | |
| Net loss · Q2-2026 | $-12M | -30% y/y |
| Adjusted EBITDA · Q2-2026 | $4M | -144% y/y |
| Cash and cash equivalents · Q2-2026 | $71M | |
| US revenue · United States · Q2-2026 | $25M | |
| Minimally invasive revenue · Minimally Invasive · Q2-2026 | $12M |
Guidance
FY26 revenue raised to $269-271M from $266.5-268.5M
Revenue guidance raised on strong Q2 performance and positive outlook for H2 2026 and 2027
Risks flagged
One-time charges from debt refinancing and restructuring may recur
“Total operating expenses included one-time charges related to debt refinancing and restructuring costs of $2.2 million” · word for word
8 May 202610-QRevenue surged 44.7% YoY to $59.9M, gross margin expanded 350bps to 70.7%, net loss narrowed 35.4% to $13.4M; new $300M credit facility closed post-quarter.earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $60M | +45% y/y |
| Net loss · Q1-2026 | $-13M | -35% y/y |
| Gross margin · Q1-2026 | 70.7% | |
| Cash and cash equivalents · 2026-03-31 | $68M | |
| Accumulated deficit · 2026-03-31 | $509M |
Risks flagged
Continued net losses and accumulated deficit
“We have incurred net losses in each year since inception, and we have financed our operations primarily through equity financings and debt financings.” · word for word
Foreign currency exposure
“The decrease was primarily due to the foreign currency fluctuations of the Brazilian real and euro as compared to the U.S. dollar in fiscal 2026 and 2025, resulting in a foreign currency transaction loss of $0.3 million” · word for word
6 May 20268-K · 2.02Revenue $60M (+45% y/y); Motiva US revenue $20M; Minimally invasive revenue $9M; Guidance: FY2026 revenue $266.5-268.5M (from $264-266M); minimally invasive >$35M (from $30M)earningsopen
Figures in the filing · each found in the filing text
| Revenue · Q1-2026 | $60M | +45% y/y |
| Motiva US revenue · Motiva US · Q1-2026 | $20M | |
| Minimally invasive revenue · Minimally invasive · Q1-2026 | $9M | |
| Gross margin · Q1-2026 | 70.7% | |
| Adjusted EBITDA · Q1-2026 | $1M | |
| Cash balance · Q1-2026 | $68M | |
| Net loss · Q1-2026 | $-13M |
Guidance
FY2026 revenue $266.5-268.5M (from $264-266M); minimally invasive >$35M (from $30M)
Raised FY2026 guidance on strong Q1 performance and momentum
Risks flagged
Cash use of $7.5M in Q1, though improved from $21.2M
“Cash use of $7.5 million compared to use of $21.2 million in the year-ago period” · word for word
30 Apr 20268-K · 1.01, 2.03Establishment Labs entered a $300M term loan credit agreement with Oaktree, refinancing existing debt and providing working capital. Interest at 8.75% with PIK option and step-downs. Matures 2031.open
Figures in the filing · each found in the filing text
| Term loan principal · 2026-04-30 | $300M | |
| Interest rate · 2026-04-30 | 8.8% |
Risks flagged
Increased leverage with $300M term loan; financial covenants require minimum liquidity and gross sales
“Credit Agreement contains financial covenants requiring minimum liquidity of $30M and minimum gross sales”
10 Apr 2026DEF 14AProxy statement for 2026 annual meeting; no material event.open
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $211M | +27% y/y |
| Net loss · FY2025 | $-51M | |
| Cash balance · 2025-12-31 | $76M |
27 Feb 202610-KEstablishment Labs filed its annual 10-K for FY2025, reporting continued losses, U.S. market launch progress, and increased debt financing.earningsopen
Figures in the filing · each found in the filing text
| Accumulated Deficit · FY2025 | $-496M | |
| Complaint Rate · FY2025 | 0.1% | |
| Medical Training Sessions · FY2025 | 607 | +154% y/y |
| R&D Expenses · FY2025 | $20M | +3% y/y |
| Number of Employees · FY2025 | 1,004 | |
| Product Liability Insurance Coverage · FY2025 | $25M |
Risks flagged
Single-source supplier risk for medical-grade silicone
“We rely on Avantor as the sole supplier of medical-grade silicone used in our Motiva Implants ... Avantor has recently informed us that it does not intend to allow the agreement to renew automatically and plans to enter into negotiations regarding future supply terms.” · word for word
Limited U.S. operating history
“We have a limited operating history in the United States and may face difficulties encountered by companies early in their commercialization in competitive and rapidly evolving markets.” · word for word
Continued losses and negative accumulated deficit
“We have incurred losses to date and expect to continue to incur losses for the foreseeable future. ... As of December 31, 2025, we had an accumulated deficit of $495.8 million.” · word for word
Currency fluctuation exposure
“As of December 31, 2025, the majority of our revenues are denominated in currencies other than the U.S. dollar - primarily the euro, the Brazilian real, and the British pound.” · word for word
Product liability and negative publicity risk
“Negative publicity concerning our products or our competitors’ products, including due to product defects or recalls and any resulting litigation, or long-term safety impacts, could harm our reputation and reduce demand for silicone breast implants” · word for word
24 Feb 20268-K · 2.02Total revenue $65M (+45% y/y); Full year revenue $211M (+27% y/y); Motiva U.S. revenue $17M; Guidance: 2026 revenue guidance $264-266M (+25-26% YoY); 2027 revenue growth projected at least 25%.earningsopen
Figures in the filing · each found in the filing text
| Total revenue · Q4-2025 | $65M | +45% y/y |
| Full year revenue · FY2025 | $211M | +27% y/y |
| Motiva U.S. revenue · U.S. · Q4-2025 | $17M | |
| Net loss from operations · Q4-2025 | $-4M | -79% y/y |
| Adjusted EBITDA · Q4-2025 | $6M | |
| Cash balance · Q4-2025 | $76M | |
| Gross margin · Q4-2025 | 70.5% |
Guidance
2026 revenue guidance $264-266M (+25-26% YoY); 2027 revenue growth projected at least 25%.
Establishment Labs raised 2026 guidance, citing strong demand and operating leverage.
Risks flagged
No material new risks; standard competitive and regulatory risks apply.
“No specific risk factor changes in the excerpt.”
12 Jan 20268-K · 2.02Revenue $211M (+27% y/y); Cash and Cash Equivalents $76M; Guidance: FY2025 revenue $210.5-211.5M, 27% growthearningsopen
Figures in the filing · each found in the filing text
| Revenue · FY2025 | $211M | +27% y/y |
| Cash and Cash Equivalents · Q4-2025 | $76M |
Guidance
FY2025 revenue $210.5-211.5M, 27% growth
Preliminary results beat expectations; management expects continued acceleration and positive FCF in 2026.
Risks flagged
Preliminary results subject to audit adjustment.
“The preliminary financial results have yet to be audited and are subject to change.” · word for word
7 Nov 202510-QEstablishment Labs reported Q3 2025 revenue of $53.8M (+33.8% YoY) and net loss of $11.1M, with US launch driving margin expansionearningsopen
Figures in the filing · each found in the filing text
| Revenue · Q3-2025 | $54M | +34% y/y |
| Revenue · 9M-2025 | $146M | +21% y/y |
| Gross Margin · Q3-2025 | 70.1% | |
| Gross Margin · 9M-2025 | 68.8% | |
| Net Loss · Q3-2025 | $-11M | |
| Net Loss · 9M-2025 | $-48M | |
| Cash and Cash Equivalents · 2025-09-30 | $71M | |
| Operating Cash Flow · 9M-2025 | $-51M | |
| US Revenue · North America · 9M-2025 | $28M | |
| EMEA Revenue · EMEA · 9M-2025 | $65M | +6% y/y |
Risks flagged
Single-source supplier concentration
“We rely on Avantor, Inc., or Avantor, as the sole supplier of medical-grade silicone used in Motiva Implants.”
Continued losses and cash burn
“We do not expect to be profitable in 2025” · word for word
China demand weakness
“Our revenue in our Asia-Pacific market decreased as compared to the corresponding period of the prior year primarily due to our China distributor still selling through inventory purchased in fiscal 2024 for the commercial launch.” · word for word
5 Nov 20258-K · 2.02Worldwide revenue $54M (+34% y/y); US Motiva sales $12M; Gross margin 70.1; Guidance: FY2025 revenue guidance raised to >$210M from $208-212Mearningsopen
Figures in the filing · each found in the filing text
| Worldwide revenue · Q3-2025 | $54M | +34% y/y |
| US Motiva sales · US · Q3-2025 | $12M | |
| Gross margin · Q3-2025 | 70.1% | |
| Loss from operations · Q3-2025 | $-4M | |
| Adjusted EBITDA · Q3-2025 | $1M | |
| Cash balance · Q3-2025 | $71M |
Guidance
FY2025 revenue guidance raised to >$210M from $208-212M
Revenue guidance raised; positive adjusted EBITDA achieved ahead of plan; US market share gains.
Risks flagged
Net loss of $11.1M despite positive adjusted EBITDA; GAAP profitability still distant.
“Net loss for the third quarter was $11.1 million” · word for word
Cash burn continues; cash decreased $19.7M from year-end 2024.
“Cash decreased $19.7 million from December 31, 2024” · word for word
Establishment Labs Holdings Inc. — questions
- What did Establishment Labs Holdings Inc. file recently?
- 14 SEC filings in the last 12 months. Latest: 8-K on 2026-10-15 — Establishment Labs entered Amendment No. 3 to its Master Supply Agreement with NuSil Technology LLC, extending the initial term to December 31, 2031, with automatic renewals. The amendment covers medical-grade silicone supply, payment terms
Every figure on this page comes from Establishment Labs Holdings Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.